Radioimmunoassay of inhibin in the serum of male monkeys

1989 ◽  
Vol 122 (2) ◽  
pp. 477-483 ◽  
Author(s):  
U. Fingscheidt ◽  
G. F. Weinbauer ◽  
D. M. Robertson ◽  
D. M. de Kretser ◽  
E. Nieschlag
Keyword(s):  
Coefficient Of Variation ◽  
Macaca Fascicularis ◽  
Serum Samples ◽  
Response Curves ◽  
Serum Pool ◽  
Normal Monkey ◽  
Interassay Coefficient ◽  
Gonadotrophin Releasing Hormone ◽  
Radioimmunoassay Method ◽  
Marked Suppression

ABSTRACT A heterologous inhibin radioimmunoassay method to measure inhibin in serum of male cynomolgus (Macaca fascicularis) and rhesus (Macaca mulatta) monkeys has been validated using a specific antibody against bovine 31 kDa inhibin and 125I-labelled 31 kDa inhibin as tracer. A serum pool from male monkeys was used as standard. Serial dilutions of normal monkey serum showed parallel logit–log dose–response curves to purified porcine and bovine inhibin as well as to a female human serum pool. The intra-assay coefficient of variation was 4·2% (n=10) and the interassay coefficient of variation 5·1% (n=10). No loss of inhibin immunoactivity was noted after storage at 23 °C for 5 days or repeated thawing and freezing of the serum samples. Serum from castrated monkeys showed undetectable levels of inhibin. Treatment with a gonadotrophin-releasing hormone agonist for 15 weeks led to a marked suppression of peripheral serum inhibin to concentrations similar to those after hypophysectomy or pituitary stalk section. Journal of Endocrinology (1989) 122, 477–483

Rapid Method for Quantitative Determination of Propoxyphene in Serum by Gas-Liquid Chromatography

1973 ◽  
Vol 19 (5) ◽  
pp. 492-495 ◽  
Author(s):  
M A Evenson ◽  
Susan Koellner
Keyword(s):  
Liquid Chromatography ◽  
Quantitative Determination ◽  
Rapid Method ◽  
Coefficient Of Variation ◽  
Therapeutic Dose ◽  
Gas Liquid Chromatography ◽  
Healthy Controls ◽  
Serum Pool ◽  
Sedative Drugs

Abstract Rapid, accurate, and precise gas-chromatographic methods are reported for measurement of propoxyphene ("Darvon") in serum. A sample of 5 ml of serum is required for quantitation in blood after a therapeutic dose of 130-195 mg of propoxyphene; in cases of overdose of propoxyphene, only 1 ml of serum is required in a "toxic method" variation. Neither serum from healthy controls or from hospitalized patients contains interfering substances. Several commonly used analgesic and sedative drugs, added to a serum pool, also did not interfere. Day-to-day precision of the therapeutic method, as measured by the coefficient of variation (CV), is 7%; the CV for the method as applied to overdose cases is less than 3%. Propoxyphene added to serum could be about 86% accounted for analytically.

How changes in the serial distribution of bronchoconstriction affect lung mechanics

1993 ◽  
Vol 74 (6) ◽  
pp. 2838-2847 ◽  
Author(s):  
F. M. Robatto ◽  
S. Simard ◽  
M. S. Ludwig
Keyword(s):  
Direct Effect ◽  
Coefficient Of Variation ◽  
Lung Parenchyma ◽  
Lung Mechanics ◽  
Response Curves ◽  
Mechanical Heterogeneity ◽  
Airway Constriction ◽  
Lung Resistance ◽  
Lung Periphery ◽  
Central Airway

It is generally accepted that methacholine (MCh) acts predominantly on the central airways and histamine (H) acts on the lung periphery. We hypothesized therefore that lung mechanics would be affected differently by H and MCh aerosols. In 12 anesthetized paralyzed open-chest mongrel dogs, we obtained MCh (0.1–30 mg/ml, n = 6) and H (0.1–30 mg/ml, n = 6) concentration-response curves. The alveolar capsule technique was used to partition lung resistance (RL) into airway (Raw) and tissue (Rti) components. The degree of mechanical heterogeneity across the lung was assessed by computing the coefficient of variation for five alveolar pressures during relaxed expirations. RL increased 823 +/- 202% after H and 992 +/- 219% after MCh. Rti increased 784 +/- 192% after H and 1,014 +/- 279% after MCh. Raw increased 1,098 +/- 297% after H and 1,275 +/- 332% after MCh. Elastance increased 342 +/- 53% after H and 423 +/- 88% after MCh. The coefficient of variation increased 279 +/- 65% after H and 252 +/- 55% after MCh. The patterns of change were similar throughout the H and MCh concentration-response curves. We conclude that H and MCh have comparable effects on lung mechanics and that the degree and pattern of heterogeneity inside the lung after constriction are the same regardless of the agent used. These data support the hypothesis that H and MCh have some similar direct effect on the lung parenchyma. Parenchymal deformation after MCh-induced central airway constriction alone would be unlikely to explain increases in Rti of this magnitude or changes in lung mechanics so similar to those induced by H.

Neonatal thyroxine screening by use of a single-tube solid-phase radioimmunoassay.

1978 ◽  
Vol 24 (10) ◽  
pp. 1755-1758 ◽  
Author(s):  
A B Bell ◽  
L H Coleman
Keyword(s):  
Mass Screening ◽  
Filter Paper ◽  
Coefficient Of Variation ◽  
Binding Proteins ◽  
Solid Phase ◽  
Serum Samples ◽  
Single Tube ◽  
Screening Programs ◽  
Quantitative Results ◽  
Solid Phase Radioimmunoassay

Abstract Filter paper discs saturated with dried blood can be used in the Immunotube solid-phase thyroxine radioimmunoassay. This assay utilizes polypropylene tubes to which antibody to thyroxine is covalently bound. The filter paper standards and samples are placed in the tubes, followed by an assay buffer that contains I125-labeled thyroxine and compounds to displace thyroxine from its binding proteins. After incubation, bound and free thyroxine are separated by aspirating or decanting the disc and buffer from the tube. The test can be used with 0.32 cm (1/8 inch) or 0.64 cm(1/4 inch) discs, and gives quantitative results that correlate well with those for serum samples. The intra-assay coefficient of variation is less than 10%. The assay may readily be mechanized with existing disc-punching equipment, and results of its use in mass screening programs are described.

Gonadotrophin-releasing hormone (GnRH) overcomes GnRH antagonist-induced suppression of LH secretion in primates

1986 ◽  
Vol 110 (1) ◽  
pp. 145-150 ◽  
Author(s):  
G. R. Marshall ◽  
F. Bint Akhtar ◽  
G. F. Weinbauer ◽  
E. Nieschlag
Keyword(s):  
Gnrh Antagonist ◽  
Receptor Occupancy ◽  
Gnrh Receptor ◽  
Dependent Manner ◽  
Response Curves ◽  
Gnrh Antagonists ◽  
Releasing Hormone ◽  
Gonadotrophin Secretion ◽  
Gonadotrophin Releasing Hormone ◽  
Lh Secretion

ABSTRACT If the suppressive effects of gonadotrophin-releasing hormone (GnRH) antagonists on gonadotrophin secretion are mediated through GnRH-receptor occupancy alone, it should be possible to restore serum gonadotrophin levels by displacing the antagonist with exogenous GnRH. To test this hypothesis, eight adult crab-eating macaques (Macaca fascicularis), weight 4·7–7·6 kg, were subjected to the following treatment regimens. A GnRH-stimulation test was performed before and 4, 12 and 24 h after a single s.c. injection of the GnRH antagonist (N-Ac-d-p-Cl-Phe1,2,d-Trp3,d-Arg6,d-Ala10)-GnRH (ORG 30276). The stimulation tests were performed with 0·5, 5·0 or 50 μg GnRH given as a single i.v. bolus. Blood was taken before and 15, 30 and 60 min after each bolus for analysis of bioactive LH and testosterone. The GnRH-challenging doses were given as follows: 0·5 μg GnRH was injected at 0 and 4 h, followed by 5·0 μg after 12 h and 50 μg after 24 h. One week later, 5·0 μg GnRH were given at 0 and 4 h, followed by 50 μg after 12 h and 0·5 μg after 24 h. Finally, after another week, the GnRH challenges began with 50 μg at 0 and 4 h, followed by 0·5 μg at 12 h and 5·0 μg at 24 h. This design permitted comparison of the LH and testosterone responses with respect to the dose of GnRH and the time after administration of GnRH antagonist. The areas under the response curves were measured and statistical evaluation was carried out by means of non-parametric two-way analysis of variance followed by the multiple comparisons of Wilcoxon and Wilcox. Four hours after the antagonist was injected, the LH and testosterone responses to all three doses of GnRH were suppressed. At the lowest dose of GnRH (0·5 μg) the responses remained reduced even after 24 h, whereas the higher doses of GnRH elicited an LH and testosterone response at 12 and 24 h which was not significantly different from that at 0 h. These data demonstrate that the suppression of LH secretion by a GnRH antagonist in vivo can be overcome by exogenously administered GnRH in a dose- and time-dependent manner, thus strongly supporting the contention that GnRH antagonists prevent gonadotrophin secretion by GnRH-receptor occupancy. J. Endocr. (1986) 110, 145–150

scholarly journals Regulation of gonadotrophin secretion by inhibin, testosterone and gonadotrophin-releasing hormone in pituitary cell cultures of male monkeys

1998 ◽  
Vol 159 (1) ◽  
pp. 103-110 ◽  
Author(s):  
U Fingscheidt ◽  
GF Weinbauer ◽  
HL Fehm ◽  
E Nieschlag
Keyword(s):  
Dose Response ◽  
Pituitary Cells ◽  
Basal Secretion ◽  
Response Curves ◽  
Gonadotrophin Secretion ◽  
Lh Release ◽  
Gonadotrophin Releasing Hormone ◽  
Dose Response Curves ◽  
Male Rhesus

The effects of bovine inhibin, testosterone and GnRH on gonadotrophin secretion by primate pituitary cells were characterized in vitro using pituitaries from six male rhesus monkeys and one male cynomolgus monkey. The effect of inhibin on basal secretion of FSH and LH was investigated. Dose-response curves in monkeys and rats were compared. GnRH dose-response curves in the presence and absence of testosterone were also examined in monkeys. In monkey pituitary cells, testosterone at a concentration of 10(-7) M had no effect on LH or FSH secretion. Inhibin suppressed FSH secretion to 50.8% of that of controls with no effect on LH. In rats, FSH secretion was suppressed to 45.0% of that of controls with a median effective dose (ED50, 95% range) of 1.298 (1.064-1.584) U/ml, compared with 1.024 (0.7204-1.455) U/ml in monkeys. In monkey pituitary cells, LH release was stimulated 9.9-fold and FSH 3.3-fold by GnRH. Testosterone had no effect on basal or GnRH-stimulated gonadotrophin release. These results support the view that the pituitary is not the target organ for the negative feedback action of testosterone in the male. In vitro, inhibin is the major regulator of FSH secretion at the pituitary level.

Pharmacokinetics and pharmacodynamics of recombinant and urinary human FSH in the male monkey (Macaca fascicularis)

1994 ◽  
Vol 141 (1) ◽  
pp. 113-121 ◽  
Author(s):  
G F Weinbauer ◽  
M Simoni ◽  
J S Hutchison ◽  
E Nieschlag
Keyword(s):  
Macaca Fascicularis ◽  
Statistical Significance ◽  
Dose Range ◽  
Dose Finding ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Serum Samples ◽  
Maximum Serum ◽  
Fsh Bioactivity

Abstract A dose-finding study was performed in adult male monkeys (Macaca fascicularis) to evaluate the pharmacokinetics and pharmacodynamics of a recombinant human FSH preparation (rhFSH). Groups of five monkeys were randomly assigned to receive single i.m. injections of 0·9% (w/v) NaCl (diluent), 6, 12 or 24 IU rhFSH/kg or 24 IU urinary human FSH/kg (uhFSH). The doses were based on an in vivo ovarian weight gain assay. Blood samples were collected 24 h before and immediately prior to injections, and 4, 8, 12, 24, 72 and 96 h after injections for determination of serum levels of immunoactive FSH by fluoroimmunoassay, bioactive FSH by an in vitro Sertoli cell assay, and inhibin and testosterone by radioimmunoassay. Inhibin was chosen as a marker for in vivo hFSH activity, since the secretion of inhibin in male monkeys is under the control of FSH. Administration of hFSH resulted in dose-related increases in serum hFSH concentrations. rhFSH and uhFSH exhibited similar pharmacokinetics. Comparable findings were obtained when serum samples were analysed for in vitro FSH bioactivity. Maximum serum hFSH levels were obtained 4–6 h after administration and the elimination half-life of hFSH was on average 18–22 h. The serum pharmacokinetics of rhFSH were linear within the dose range explored. Baseline inhibin concentrations varied significantly between groups. However, when the changes in inhibin concentrations were normalized to the baseline values (per cent change, area under curve and maximum inhibin level), a dose-dependent stimulatory effect of rhFSH on serum inhibin was evident. This effect attained statistical significance with doses of 24 IU rhFSH/kg and 24 IU uhFSH/kg, and the serum inhibin responses to rhFSH and uhFSH were not significantly different. No significant differences were observed with regard to the serum concentrations of testosterone between the diluentand hFSH-treated groups. It was concluded that rhFSH is bioactive in terms of stimulating testicular inhibin production in the male monkey and that the pharmacokinetic properties of rhFSH and uhFSH are similar. Journal of Endocrinology (1994) 141, 113–121

scholarly journals Adsorbed soluble [3H]elastin as substrate for proteinase activity. A new microassay technique

1984 ◽  
Vol 218 (2) ◽  
pp. 645-648 ◽  
Author(s):  
H S Jensen
Keyword(s):  
Coefficient Of Variation ◽  
Proteinase Activity ◽  
Elastase Activity ◽  
Pancreatic Elastase ◽  
Passive Adsorption ◽  
Interassay Coefficient ◽  
Scintillation Fluid ◽  
Porcine Pancreatic Elastase

A microassay for elastase activity has been designed. Microtubes are coated with soluble elastin substrate by passive adsorption to the tube walls. On contact with enzymes in test samples, radioactivity is released into the sample buffer, which is then transferred to vials containing scintillation fluid without further processing. Porcine pancreatic elastase (EC 3.4.21.11) is easily detected in concentrations down to 8 micrograms/litre. The interassay coefficient of variation (CV) was below 10% for values above 50 micrograms/litre. The assay is rapid, precise, economical and sensitive.

International Federation of Clinical Chemistry Standardization Project for Measurements of Apolipoproteins A-I and B. II. Evaluation and Selection of Candidate Reference Materials

1992 ◽  
Vol 38 (5) ◽  
pp. 658-662 ◽  
Author(s):  
J J Albers ◽  
S M Marcovina ◽  
H Kennedy
Keyword(s):  
Reference Materials ◽  
Clinical Chemistry ◽  
Collaborative Study ◽  
Second Phase ◽  
Serum Samples ◽  
Apo B ◽  
Common Reference ◽  
Test Systems ◽  
Serum Pool ◽  
Fresh Frozen

Abstract The first phase of an international collaborative study for standardization of test systems for measuring apolipoprotein (apo) A-I and apo B demonstrated that uniformity of apo A-I and apo B measurements can be achieved if suitable common reference materials are used to calibrate the different systems. The objective of the second phase was to evaluate the linearity and parallelism or proportionality of the candidate reference materials selected in phase one and to determine whether any of them could be proposed as international reference materials. We evaluated the proposed reference materials with 37 test systems for apo A-I and 38 for apo B, involving 23 manufacturers and five research laboratories. Two lyophilized preparations were proposed for apo A-I, SP1 from Behringwerke AG and SP2 from Daiichi Pure Chemicals Co., and two liquid preparations were proposed for apo B, SP3 from Behringwerke AG and SP4 from Reagents Applications. The linearity of the candidate reference materials was compared with the linearity of a frozen serum pool or interim serum reference material distributed to all the participants and with that of a fresh serum pool prepared by each participant. SP1 and SP3 exhibited linearity and parallelism similar to that of the fresh frozen serum pool and had among-laboratory CVs less than or similar to those obtained on normolipidemic serum samples (approximately 6% for apo A-I and approximately 7% for apo B).

Sustained inhibition of sperm production and inhibin secretion induced by a gonadotrophin-releasing hormone antagonist and delayed testosterone substitution in non-human primates (Macaca fascicularis)

1989 ◽  
Vol 123 (2) ◽  
pp. 303-310 ◽  
Author(s):  
G. F. Weinbauer ◽  
S. Khurshid ◽  
U. Fingscheidt ◽  
E. Nieschlag
Keyword(s):  
Sertoli Cell ◽  
Macaca Fascicularis ◽  
Gnrh Antagonist ◽  
Cell Activity ◽  
Serum Testosterone ◽  
Sperm Production ◽  
Entire Treatment Period ◽  
Releasing Hormone ◽  
Testosterone Substitution ◽  
Gonadotrophin Releasing Hormone

ABSTRACT Since the concomitant administration of a gonadotrophin-releasing hormone (GnRH) antagonist and testosterone suppresses sperm production only incompletely, the feasibility of treatment with a GnRH antagonist and delayed testosterone supplementation for sustained suppression of sperm production in a non-human primate model was investigated. Adult cynomolgus monkeys (Macaca fascicularis; five/group) received daily s.c. injections of the GnRH antagonist [N-acetyl-d-2-naphthyl-Ala1,d-4-chloro-Phe2,d-pyridyl-Ala3,nicotinyl-Lys5,d- nicotinyl - Lys6, isopropyl-Lys8,d-Ala10]-GnRH of either 450 or 900 μg/kg for 18 weeks. During week 6 of the GnRH antagonist treatment, all monkeys were given a single i.m. injection of 40 mg of a long-acting testosterone ester (testosterone-trans-4-n-butylcyclo-hexanecarboxylate; 20-Aet-1). Within 1 week, serum LH bioactivity was suppressed in both groups and remained low throughout the entire treatment period. Similarly, concentrations of serum testosterone declined precipitously. During week 6, substitution with testosterone restored concentrations of serum testosterone into the pretreatment range. Concentrations of serum inhibin declined within 1 week and remained suppressed during the period of treatment with the GnRH antagonist. Testicular volumes were reduced to approximately 25% of pretreatment values in both groups by week 8 and stayed in that range during the remaining period of administration of the GnRH antagonist. During the first 6 weeks of administration of the GnRH antagonist, the ejaculatory response to electrostimulation and the volume of the ejaculates diminished with time. Supplementation with testosterone during week 6 restored the ejaculatory responses within 2–3 weeks. From week 9 of GnRH antagonist treatment onwards, all monkeys given 450 μg/kg and four monkeys given 900 μg/kg produced azoospermic ejaculates. The fifth animal in the latter group became azoospermic during week 13. Azoospermia persisted throughout the entire period of treatment with the GnRH antagonist and for a further 7–13 weeks. All suppressive effects of administration of GnRH antagonist were reversible. During the recovery phase the increase in testicular volumes paralleled an increase in concentrations of serum inhibin. The suppression of inhibin levels during the period of administration of testosterone indicates that Sertoli cell activity was not restimulated by testosterone. In conclusion, GnRH antagonist treatment with delayed supplementation with testosterone might serve as a model for further research towards the development of an endocrine male contraceptive. The recovery pattern of serum levels of inhibin suggests that inhibin could serve as a marker for Sertoli cell activity. Journal of Endocrinology (1989) 123, 303–310

Development of ELISAs for Quantification of HMFG1-Specific Human Anti-Mouse IgG and IgM Antibodies

2007 ◽  
Vol 22 (3) ◽  
pp. 167-171
Author(s):  
A.L.M. Oei ◽  
O.C. Boerman ◽  
A. Geurts-Moespot ◽  
J.E. van Eerd ◽  
D. van Tienoven ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Standard Dose ◽  
Antibody Therapy ◽  
Phase Iii ◽  
Analytical Sensitivity ◽  
Serum Samples ◽  
Response Curves ◽  
Phase Iii Trial ◽  
Reference Preparation ◽  
Capture Antibody

The aim of this study was to develop and validate ELISAs for quantification of HAMA-IgM and HAMA-IgG in serum of patients with ovarian cancer who enrolled in a large international randomized phase III trial of intraperitoneal Yttrium-90-labeled HMFG1 murine monoclonal antibody therapy. The capture antibody of these 2 assays was the murine antibody HMFG1, while mouse anti-human IgM-HRP or mouse anti-human IgG(Fc)-HRP served as tracer antibodies. A pool of HAMA-positive serum samples was used to prepare a series of assay standards and another pool served as reference preparation. The analytical sensitivity of the HAMA-IgM assay was 2.5 arbitrary units per mL (AU/mL) and 4.7 AU/mL for the HAMA-IgG ELISA. Diluted serum samples showed good parallelism with the HAMA-IgM and HAMA-IgG standard dose-response curves. Within-assay coefficient of variation was 7.5% for HAMA-IgM and 6.5% for HAMA-IgG. Between-assay variation was 14.2% for HAMA-IgM and 15.3% for HAMA-IgG. The developed HAMA-IgM and HAMA-IgG ELISAs show satisfactory reliability criteria (sensitivity, parallelism and precision) and are suitable for monitoring of HAMA-IgM and HAMA-IgG responses in ovarian cancer patients. These ELISAs will be used to monitor the development of HAMAs in patients who received radioimmunotherapy with murine HMFG1.

Sign in / Sign up

Export Citation Format

Share Document